BioPharma Dive November 29, 2022
Ben Fidler

The nascent field of drug research has spawned several startups in recent years, but faces tough technological questions.

Three weeks ago, a well-funded biotechnology startup called Faze Medicines abruptly shut down.

The specific reasons for Faze’s closure aren’t yet known. In a statement then, Third Rock Ventures, which led Faze’s initial $81 million funding round in 2020, said the company’s scientific progress didn’t “meet our bar for further investment.” Management recommended it close and the board agreed, the investor said.

Faze’s fate is a lesson for a promising field of drug research into “biomolecular condensates” — microscopic, fluid-like droplets found within cells that partake in an array of important functions.

Identified in 2009 in the cells of worms by researchers...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Pharma / Biotech
Covid’s scientific silver lining: A chance to watch the human immune system respond in real time
How GLP-1’s moved from research labs to national TV
Understanding the politics of drug pricing in the United States
Opinion: Oprah kicked off a national conversation on obesity and GLP-1 drugs. Let’s have it
Brazil’s plan for low-cost CAR-Ts

Share This Article